AbbVie Inc. $ABBV Shares Sold by Railway Pension Investments Ltd

Railway Pension Investments Ltd decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 1.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 792,949 shares of the company’s stock after selling 7,900 shares during the quarter. AbbVie makes up 2.5% of Railway Pension Investments Ltd’s portfolio, making the stock its 12th largest holding. Railway Pension Investments Ltd’s holdings in AbbVie were worth $199,538,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ABBV. State Street Corp lifted its holdings in AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after purchasing an additional 1,119,274 shares during the period. Geode Capital Management LLC increased its stake in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after buying an additional 4,190,487 shares during the period. Bank of America Corp DE raised its position in shares of AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after buying an additional 356,394 shares in the last quarter. Norges Bank acquired a new stake in shares of AbbVie in the 4th quarter worth approximately $5,865,055,000. Finally, Capital Research Global Investors lifted its stake in shares of AbbVie by 0.7% in the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after acquiring an additional 177,370 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $248.75 on Wednesday. The firm has a 50 day simple moving average of $254.66 and a 200 day simple moving average of $230.36. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company has a market cap of $439.49 billion, a PE ratio of 70.27, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is currently 195.48%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ABBV. Piper Sandler raised their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Cantor Fitzgerald upped their target price on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. HSBC reiterated a “buy” rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Finally, Canaccord Genuity Group raised their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.